NASDAQ$BCPC

Balchem Corporation · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Balchem's Q3 2024 earnings were reported, showing revenue growth and record earnings.

Balchem Corporation reported strong third quarter financial results with solid revenue growth and record earnings from operations and adjusted EBITDA. Net sales were $239.9 million, net earnings were $33.8 million, adjusted EBITDA was $64.4 million, and free cash flow was $42.2 million.

  • Net sales increased by 4.3% compared to the prior year quarter, reaching $239.9 million.
  • Adjusted EBITDA reached a record $64.4 million, a 7.6% increase from the prior year quarter.
  • GAAP net earnings increased by 16.4% from the prior year quarter, totaling $33.8 million.
  • The company saw strong sales growth and earnings from operations in both the Human Nutrition and Health and Specialty Products segments.

Headline financials

Total Revenue

$240M

Previous: $230M+4.3%
EPS

$1.03

Previous: $0.90+14.4%
Adjusted EBITDA

$71.4M

No prior period
Capital Expenditures

-$9.15M

Previous: -$25.8M+64.6%
Free Cash Flow

$33.8M

Previous: $3.24M+943.7%
Net Income

$33.8M

Previous: $29.1M+16.4%
Operating Income

$48M

Previous: $43.6M+10.0%
Gross Profit

$85.4M

Previous: $76.5M+11.5%
Cash & Equivalents

$73.7M

Previous: $77M-4.2%
Total Assets

$1.6B

Previous: $1.6B-0.4%
Stock-Based Comp

$4.15M

Previous: $3.75M+10.7%

Revenue & EPS history

Balchem · Revenue · Quarterly

$240M

Q3 2024+4.3%vs Q3 2023
Beat estimate in 7 of 14 quarters(50%)
ActualEstimate

Revenue by segment

Balchem · $228M total across 3 segments · Q3 2023

  • Human Nutrition & Health
    $144M+1.3%
  • Animal Nutrition & Health
    $53.9M-17.8%
  • Specialty Products
    $30M+1.2%

Forward guidance

The Balchem team delivered another strong quarter, highlighting the resilience of the business model and remains confident in the long-term growth outlook.

Tailwinds

  • Recent product launches in both the Human and Animal Nutrition and Health segments.
  • Focus on bringing innovative solutions for the health and nutritional needs of the world.
  • Progress on strategic growth initiatives.
  • Strong sales growth and earnings from operations in both our Human Nutrition and Health and Specialty Products segments.
  • The Balchem team delivered another strong quarter, once again highlighting the resilience of our business model.

Headwinds

  • Challenging market environment.
  • Lower sales in the monogastric species markets in the Animal Nutrition and Health segment.
  • Higher operating expenses in the Animal Nutrition and Health segment.
  • Higher compensation-related costs and transaction costs.
  • Higher effective tax rate was primarily due to lower tax benefits from stock-based compensation and certain higher U.S. state taxes.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

+0.0%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+0.9%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+25.0%

Q1 2014

Best reaction

-16.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-6.8%-7.0%-9.7%
Q4 2025-2.3%+2.6%-7.4%
Q3 2025+4.1%+3.9%+1.3%
Q1 2025-2.6%-1.5%+4.8%
Q4 2024+1.5%+7.0%-0.1%
Q3 2024+2.8%+1.6%+9.8%
Q2 2024+3.9%+1.5%-1.2%
Q1 2024-1.8%-3.0%-8.8%
Q4 2023+7.4%+5.0%+6.8%
Q3 2023-5.0%-4.1%+1.1%
Q2 2023+4.8%+5.0%+7.1%
Q1 2023+1.7%+0.5%+5.2%
Q4 2022-2.0%-0.2%-7.7%
Q3 2022-0.6%-0.5%+5.4%
Q2 2022-5.2%-6.6%+2.3%
Q1 2022+1.6%-0.9%-10.5%
Q4 2021+1.0%-0.7%+1.2%
Q3 2021-0.8%+2.3%+7.9%
Q2 2021-0.8%-2.5%+2.7%
Q1 2021-0.2%-0.1%+0.5%
Q4 2020+5.4%+6.4%+10.7%
Q3 2020-1.7%-0.5%+3.3%
Q2 2020+4.6%+4.7%+0.3%
Q1 2020-5.4%-3.9%-9.3%
Q4 2019-10.7%-13.3%-15.9%
Q3 2019+2.9%+1.2%-0.8%
Q2 2019-16.3%-15.9%-13.5%
Q1 2019+1.1%+4.0%+9.4%
Q4 2018+8.0%+12.4%+10.7%
Q3 2018-4.9%-4.9%-13.7%
Q2 2018+1.1%+1.3%+10.1%
Q1 2018-1.3%+2.2%+7.9%
Q4 2017+2.3%+5.9%+8.6%
Q3 2017+1.0%-0.7%+1.3%
Q2 2017-2.6%-3.9%-1.8%
Q1 2017-3.3%-5.3%-1.8%
Q4 2016+5.2%+2.2%-2.5%
Q3 2016-4.5%+0.8%+12.3%
Q2 2016+1.3%+2.0%+8.7%
Q1 2016+0.3%
Q4 2015-0.4%
Q3 2015-2.0%
Q2 2015+5.2%
Q1 2015-0.5%
Q4 2014-3.4%
Q3 2014+6.7%
Q2 2014+2.5%
Q1 2014+25.0%
Q4 2013+0.4%
Q3 2013-4.9%
Q2 2013+1.3%
Q1 2013-2.3%
Q4 2012+0.8%
Q3 2012-10.5%
Q2 2012+5.9%
Q1 2011+2.1%
Q4 2011+2.1%
Q1 2012+2.4%
Q1 2010-4.1%
Q4 2009-4.1%
Q3 2010-3.2%
Q3 2011-3.2%
Q2 2011+1.0%
Q4 2010+1.0%
Q2 2010+1.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro